Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obliations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services Ltd, has received a suspension order for a Drug License from the Food & Drug Administration, Maharashtra. The suspension is for five days for a store located at Samta Nagar, Nashik, Maharashtra. The order was received on May 6, 2026. The violation is under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has disclosed a potential revenue loss of Rs 0.75 lakh due to this suspension.
The financial impact is minimal at Rs 0.75 lakh, representing just one store suspension out of the company's overall pharmacy network. However, it indicates a regulatory compliance issue at a subsidiary level that investors should monitor.